Larry A. Sklar

Solubilization and display of G protein-coupled receptors on beads for real-time fluorescence and flow cytometric analysis.

Flow cytometric analysis of ligand-receptor interactions and molecular assemblies.

Flow cytometry for drug discovery, receptor pharmacology and high-throughput screening.

Characterization of a Cdc42 protein inhibitor and its use as a molecular probe.

Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.

The University of New Mexico Center for Molecular Discovery.

Identification of isoxsuprine hydrochloride as a neuroprotectant in ischemic stroke through cell-based high-throughput screening.

A high throughput flow cytometric assay platform targeting transporter inhibition.

FRET detection of lymphocyte function-associated antigen-1 conformational extension.

Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair.

Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases.

Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia.

A High-Throughput Flow Cytometry Assay for Identification of Inhibitors of 3',5'-Cyclic Adenosine Monophosphate Efflux.

High-Throughput Screening Approach for Identifying Compounds That Inhibit Nonhomologous End Joining.

Autophagy, Inflammation, and Metabolism (AIM) Center of Biomedical Research Excellence: supporting the next generation of autophagy researchers and fostering international collaborations.

Clioquinol: To harm or heal.

Autophagy, Inflammation, and Metabolism (AIM) Center in its second year.

A Selective Ligand for Estrogen Receptor Proteins Discriminates Rapid and Genomic Signaling.

Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy.

Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties.

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.

A phenotypic screen for compounds that reverse cAMP-mediated suppression of T cell functions.